![Mark McKenna](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark McKenna
Vorsitzender bei
APOGEE THERAPEUTICS, INC.
Vermögen: 2 Mio $ am 31.05.2026
Profil
Mark C.
McKenna is the founder of Mirador Therapeutics, Inc., founded in 2024, where the title held is Chairman & Chief Executive Officer.
Current jobs include Chairman at Apogee Therapeutics, Inc. since 2023; Vice Chairman at NewAmsterdam Pharma Co. NV since 2024; Director at Spyre Therapeutics, Inc. since 2024; Director at Prometheus Laboratories, Inc.; Managing Director & Chief Investment Officer at Mckenna Capital, LLC since 2023; Independent Director at Helix Acquisition Corp.
III; and Independent Director at Perceptive Capital Solutions Corp.
since 2024.
Former jobs include Chairman, President & Chief Executive Officer at Prometheus Biosciences, Inc. from 2021 to 2023; Independent Director at Helix Acquisition Corp.
II.
from 2024 to 2025; Director at Rebalance Health, Inc.; Senior Vice President & GM-US Vision Care at Bausch & Lomb, Inc. from 2014 to 2016; and President at Salix Pharmaceuticals Ltd. from 2016 to 2019.
Education includes undergraduate studies at Arizona State University and an MBA from Azusa Pacific University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 09.06.2026 | 20’000 ( 0.04% ) | 2 Mio $ | 31.05.2026 | |
1.39% | 01.05.2026 | 30’000 ( 1.39% ) | 334 200 $ | 31.05.2026 |
0.7% | 23.01.2026 | 30’000 ( 0.7% ) | 306 300 $ | 31.05.2026 |
| 15.04.2026 | 2’320 ( 0% ) | 78 138 $ | 31.05.2026 | |
| 27.05.2026 | 0 ( -.--% ) | - $ | 31.05.2026 |
Aktive Positionen von Mark McKenna
| Unternehmen | Position | Beginn |
|---|---|---|
| APOGEE THERAPEUTICS, INC. | Vorsitzender | 17.08.2023 |
| SPYRE THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.02.2024 |
| FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Direktor/Vorstandsmitglied | 16.07.2024 |
Prometheus Laboratories, Inc.
 Prometheus Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel pharmaceutical and diagnostic products | Direktor/Vorstandsmitglied | - |
Mckenna Capital, LLC
 Mckenna Capital, LLC Mckenna Capital, LLC is a private equity real estate investment firm specializing in passive real estate syndications, focusing on asset classes such as multifamily apartments, self-storage facilities, manufactured and mobile home parks, and niche sectors like senior living and express car washes. The private company is based in Malvern, PA. The firm acts as co-general partners in joint ventures, enabling accredited and financially sophisticated investors to pool capital with experienced operators. The company emphasizes creating passive income streams and long-term wealth through value-add strategies for income-producing properties. Investors benefit from diversified portfolios, consistent cash flow, equity appreciation, mortgage amortization, and tax advantages, with investment opportunities offered through confidential private offering memoranda. The firm provides educational resources and an investor portal for tracking investments. The company was founded by Stephen T. McGrath. Mark C. Mckenna has been the CEO of the company since 2023. | Vorstandsvorsitzender | 01.06.2023 |
Ehemalige bekannte Positionen von Mark McKenna
| Unternehmen | Position | Ende |
|---|---|---|
| PROMETHEUS BIOSCIENCES, INC. | Vorstandsvorsitzender | 16.06.2023 |
| SALIX PHARMACEUTICALS, LTD. | Präsident | 01.08.2019 |
Bausch & Lomb, Inc.
 Bausch & Lomb, Inc. Medical SpecialtiesHealth Technology Manufactures and supplies contact lenses | Corporate Officer/Principal | 01.01.2016 |
Rebalance Health, Inc.
 Rebalance Health, Inc. Pharmaceuticals: OtherHealth Technology Manufactures supplements for health and stress management & sells through online | Direktor/Vorstandsmitglied | - |
Ausbildung von Mark McKenna
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
63
Beziehungen ersten Grades
11
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 11 |
|---|---|
Bausch & Lomb, Inc.
Bausch & Lomb, Inc. Medical SpecialtiesHealth Technology Manufactures and supplies contact lenses | Health Technology |
Salix Pharmaceuticals Ltd.
 Salix Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops prescription drugs | Health Technology |
Spyre Therapeutics, Inc.
 Spyre Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biotechnology company | Health Technology |
Arizona State University
 Arizona State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Azusa Pacific University
 Azusa Pacific University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Prometheus Laboratories, Inc.
Prometheus Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel pharmaceutical and diagnostic products | Health Technology |
Mckenna Capital, LLC
Mckenna Capital, LLC Mckenna Capital, LLC is a private equity real estate investment firm specializing in passive real estate syndications, focusing on asset classes such as multifamily apartments, self-storage facilities, manufactured and mobile home parks, and niche sectors like senior living and express car washes. The private company is based in Malvern, PA. The firm acts as co-general partners in joint ventures, enabling accredited and financially sophisticated investors to pool capital with experienced operators. The company emphasizes creating passive income streams and long-term wealth through value-add strategies for income-producing properties. Investors benefit from diversified portfolios, consistent cash flow, equity appreciation, mortgage amortization, and tax advantages, with investment opportunities offered through confidential private offering memoranda. The firm provides educational resources and an investor portal for tracking investments. The company was founded by Stephen T. McGrath. Mark C. Mckenna has been the CEO of the company since 2023. | |
Prometheus Biosciences, Inc.
 Prometheus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops medicines for immune-mediated diseases | Health Technology |
Rebalance Health, Inc.
Rebalance Health, Inc. Pharmaceuticals: OtherHealth Technology Manufactures supplements for health and stress management & sells through online | Health Technology |
NewAmsterdam Pharma Co. NV
 NewAmsterdam Pharma Co. NV Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that researches, develops, manufactures and commercializes transformative therapies for cardio-metabolic diseases | Health Technology |
Apogee Therapeutics, Inc.
 Apogee Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops therapies for immunological and inflammatory disorders | Health Technology |
Wählen Sie MarketScreener 
